RA0684

antibody from Oursmab

Targeting: SIGLEC8 MGC59785, SAF2, SIGLEC-8, SIGLEC8L

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0684

Provider

Oursmab

Product name

Lirentelimab (Biosimilar Reference Antibody) (SIGLEC8)

Antibody type

Monoclonal

Description

Lirentelimab (also known as AK002) is an investigational, humanized monoclonal antibody that targets sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8), an inhibitory receptor selectively expressed on eosinophils, mast cells, and to a lesser extent on basophils. By engaging Siglec-8, lirentelimab induces antibody-dependent cellular cytotoxicity (ADCC) and apoptosis in eosinophils and inhibits mast cell activation. This dual mechanism aims to deplete pathogenic eosinophils and dampen mast cell-mediated inflammation. It is being developed for the treatment of eosinophil and mast cell-driven diseases, with clinical trials in eosinophilic gastritis/gastroenteritis (EG/EoG), eosinophilic esophagitis (EoE), and chronic spontaneous urticaria (CSU).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.